Stocks and Investing
Stocks and Investing
Wed, November 1, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, October 31, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Kristen Kluska Downgraded (SRPT) to Hold and Decreased Target to $40 on, Oct 31st, 2023
Kristen Kluska of Cantor Fitzgerald, Downgraded "Sarepta Therapeutics, Inc." (SRPT) to Hold and Decreased Target from $166 to $40 on, Oct 31st, 2023.
Kristen has made no other calls on SRPT in the last 4 months.
There is 1 other peer that has a rating on SRPT. Out of the 1 peers that are also analyzing SRPT, 0 agree with Kristen's Rating of Hold.
This is the rating of the analyst that currently disagrees with Kristen
- Uy Ear of "Mizuho" Reiterated at Strong Buy and Held Target at $160 on, Tuesday, September 26th, 2023
Contributing Sources